Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
The incretin hormones are intestinal polypeptides that enhance postprandial insulin secretion. Gastric inhibitory polypeptide (GIP) was initially thought to regulate gastric acid secretion, whereas glucagon-like peptide-1 (GLP-1) was discovered as a result of a systematic search for intestinal insulinotropic products of proglucagon gene expression. The incretin effect is markedly impaired or absent in patients with type 2 diabetes because of decreased secretion of GLP-1 and a loss of the insulinotropic effects of GIP. Metabolic control can be restored or greatly improved by administration of exogenous GLP-1, but this peptide is almost immediately degraded by dipeptidyl peptidase IV (DPP-IV), and therefore has little clinical value. DPP-IV-resistant analogues (incretin mimetics) have been identified or developed, and inhibitors of DPP-IV have also proved effective in protecting endogenous GLP-1 (and GIP) from degradation. Both principles have been tested in clinical studies. The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years. The DPP-IV inhibitors, given once or twice daily by mouth, also appear to provide lasting improvement in HbA(1)c, but are weight-neutral. The first incretin mimetic has reached the market in the US, and applications for approval of the first inhibitors are expected to be filed early in 2006.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The major effect of incretins is the potentiation of glucose-stimulated insulin secretion by pancreatic β-cells [14,15,16,17].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“controlled pivotal phase III studies involving 1,494 patients, in whom exenatide was given for 30 weeks as an add-on therapy to type 2 diabetic patients inadequately treated with sulfonylureas [68], metformin [69] or a combination of metformin and sulfonylureas [70].”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“In addition, GLP-1 was shown to inhibit appetite and food intake, both in healthy individuals [36], and in patients with type 2 diabetes [37].”
BackgroundSelf-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Research works printed but not linked: 4
- 26. Holst JJ, Orskov C, Schwartz TW, Buhl T, Baldissera F (1986) Proglucagon 78-107, a potent insulinotropic hormone from the lower small intestine. Diabetologia 29:549A (Abstract)
- 50. Larsen J, Jallad J, Damsbo P (1996) One-week continuous infusion of GLP-1(7-37) improves glycemic control in NIDDM. Diabetes 45:233A (Abstract)
- 54. Ehlers MRW, Roderick EH, Schneider RL, Kipnes MS (2002) Continuous subcutaneous infusion of recombinant GLP-1 for 7 days dose-dependently improved glycemic controls in type 2 diabetes. Diabetes 51:A579 (Abstract)
- 74. Nauck M, Hompesch M, Filipczak R et al (2004) Liraglutide as add-on to metformin in type 2 diabetes: significant improvement in glycaemic control with a reduction in body weight compared with glimepiride. Diabetologia 47:A281 (Abstract)
Cited by
Items 101–200 of 253
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
Sharma, A., Virmani, T., Sharma, A., Chhabra, V., Kumar, G., Pathak, K., & Alhalmi, A. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s369712 · Cited by 36
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch25 · Cited by 37
Andrews, C. N., Bharucha, A. E., Camilleri, M., Low, P. A., Seide, B. M., Burton, D. D., Baxter, K. L., & Zinsmeister, A. R. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00403.2006 · Cited by 35
Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat
Yang, H., Li, H., Wang, Z., Shi, Y., Jiang, G., & Zeng, F. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.06.042 · Cited by 34
Svensson, A. M., Östenson, C., Efendić, S., & Jansson, L. E. (2007) · Clinical Science · doi:10.1042/cs20060272 · Cited by 34
Pathogenesis of Type 2 Diabetes Mellitus
Leahy, J. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_2 · Cited by 32
Using Computer-aided Drug Design and Medicinal Chemistry Strategies in the Fight Against Diabetes
Semighini, E. P., Resende, J. A., de Andrade, P., Morais, P. A. B., Carvalho, I., Taft, C. A., & da Silva, C. H. T. D. P. (2011) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2011.10508606 · Cited by 32
Olurishe, C. O., Kwanashie, H. O., Zezi, A. U., DANJUMA, N. M., & Mohammed, B. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.10.065 · Cited by 31
Xiong, X., Shao, W., & Jin, T. (2012) · Islets · doi:10.4161/isl.23345 · Cited by 30
Kirino, Y., Kamimoto, T., Sato, Y., Kawazoe, K., Minakuchi, K., & Nakahori, Y. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.463 · Cited by 30
Li, X. C., & Zhuo, J. L. (2007) · Clinical Science · doi:10.1042/cs20070040 · Cited by 30
Iwase, Y., Kamei, N., & Takeda‐Morishita, M. (2015) · Pharmacology & Pharmacy · doi:10.4236/pp.2015.63020 · Cited by 29
Yim, C., Mikkola, K., Fagerholm, V., Elomaa, V.-V., Ishizu, T., Rajander, J., Schlesinger, J., Roivainen, A., Nuutila, P., & Solin, O. H. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.06.012 · Cited by 29
Diabetes: advances in treatment
Cohen, N. D., & Shaw, J. E. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01369.x · Cited by 29
The pleiotropic cardiovascular effects of dipeptidyl peptidase‐4 inhibitors
Avogaro, A., & Fadini, G. P. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13611 · Cited by 28
Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer’s disease?
Li, L. (2007) · Neuroscience Bulletin · doi:10.1007/s12264-007-0009-y · Cited by 28
Sato, Y., Koshioka, S., Kirino, Y., Kamimoto, T., Kawazoe, K., Abe, S., Minakuchi, K., & Nakahori, Y. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.10.019 · Cited by 28
Long-acting peptidomimetics based DPP-IV inhibitors
Jadav, P., Bahekar, R. H., Shah, S. R., Patel, D. N., Joharapurkar, A. A., Kshirsagar, S. G., Jain, M. R., Shaikh, M., & Sairam, K. V. V. M. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.078 · Cited by 28
Ahmed, A. E., Ankireddypalli, A. R., Harindhanavudhi, T., Moran, A., & Moheet, A. A. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100375 · Cited by 27
Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy
Wang, S., Li, B., Li, C. G., Cui, W., & Miao, L. (2015) · Journal of Diabetes Research · doi:10.1155/2015/962383 · Cited by 27
Green, J. B., & Feinglos, M. N. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0008-9 · Cited by 27
Effects of glucagon‐like peptide‐1 and sympathetic stimulation on gastric accommodation in humans1
Andrews, C. N., Bharucha, A. E., Camilleri, M., Low, P. A., Seide, B. M., Burton, D. D., Nickander, K. K., Baxter, K. L., & Zinsmeister, A. R. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.00923.x · Cited by 26
What are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 26
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00942-2 · Cited by 25
Cox, J. M., Chu, H. D., Kuethe, J. T., Gao, Y., Scapin, G., Eiermann, G. J., He, H., Li, X., Lyons, K. A., Metzger, J. M., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.020 · Cited by 24
Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Gallwitz, B. (2010) · Drug Safety · doi:10.2165/11319130-000000000-00000 · Cited by 24
Structure–activity-relationship of amide and sulfonamide analogs of omarigliptin
Chen, P., Feng, D., Qian, X., Apgar, J. M., Wilkening, R. R., Kuethe, J. T., Gao, Y., Scapin, G., Cox, J. M., Doss, G. A., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.070 · Cited by 23
Information in diabetes care: is there a need to dumb down even more?
Kerr, D. E. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02135.x · Cited by 23
Tzefos, M., Harris, K., & Brackett, A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q379 · Cited by 21
Saito, R., So, M., Motojima, Y., Matsuura, T., Yoshimura, M., Hashimoto, H., Yamamoto, Y., Kusuhara, K., & Ueta, Y. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12400 · Cited by 22
Liraglutide for treating type 1 diabetes
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1160050 · Cited by 22
Self-citationImidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes
Chen, P., Caldwell, C. G., Mathvink, R. J., Leiting, B., Marsilio, F., Patel, R. A., Wu, J. K., He, H., Lyons, K. A., Thornberry, N. A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.030 · Cited by 22
Nishio, Y., Kimura, H., Sawada, N., Sugaru, E., Horiguchi, M., Ono, M., Furuta, Y., Sakai, M., Masui, Y., Otani, M., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.042 · Cited by 21
Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin
Ateyya, H. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.07.022 · Cited by 21
Kaas, A., Andersen, M. L. M., Fredheim, S., Hougaard, P., Buschard, K., Petersen, J. S., de Beaufort, C. E., Robertson, K. J., Hansen, L., Mortensen, H. B., et al. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00812.x · Cited by 21
Eiki, J., Saeki, K., Nagano, N., Iino, T., Yonemoto, M., Takayenoki-Iino, Y., Ito, S., Nishimura, T., Satô, Y., Bamba, M., et al. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0528 · Cited by 20
Watada, S., Yu, Y., Fischman, A. J., Kurihara, T., Shen, C.-A., Tompkins, R. G., & Fagan, S. P. (2013) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e31828a8ede · Cited by 20
Fors, A., Forslund, T., Sundström, A., & Wettermark, B. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03823-9 · Cited by 19
Eraky, S. M., Ramadan, N. M., & El‐Magd, N. F. A. (2021) · Cell Biochemistry and Function · doi:10.1002/cbf.3678 · Cited by 19
Duffy, J. L., Kirk, B. A., Wang, L., Eiermann, G. J., He, H., Leiting, B., Lyons, K. A., Patel, R. A., Patel, S. B., Petrov, A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.066 · Cited by 19
Laferrère, B. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.01.010 · Cited by 18
Cariou, B. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.04.003 · Cited by 19
Bailey, C. J. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0057-y · Cited by 18
Mirghani, H. O., Alamrani, S. A. S., Alkonani, A. A., & Madshush, A. M. A. A. (2023) · Cureus · doi:10.7759/cureus.49122 · Cited by 17
Medicinal Chemistry of Glucagon-Like Peptide Receptor Agonists
Jones, L. H., & Price, D. A. (2013) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-62652-3.00002-8 · Cited by 19
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Ichikawa, M., Hirayama, T., Fukushima, M., Kitazawa, I., Kojima, K., Sakai, T., Takatsu, Y., & Ohtaki, T. (2018) · ACS Omega · doi:10.1021/acsomega.8b00467 · Cited by 16
Glage, S., Klinge, P. M., Miller, M. C., Wallrapp, C., Geigle, P., Hedrich, H. J., & Brinker, T. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-18 · Cited by 16
Bailey, C. J., & Krentz, A. J. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch29 · Cited by 16
Chen, P., Caldwell, C. G., Ashton, W. T., Wu, J. K., He, H., Lyons, K. A., Thornberry, N. A., & Weber, A. E. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.060 · Cited by 15
Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy
Li, L. (2008) · Clinical Medicine Insights Pathology · doi:10.4137/cpath.s667 · Cited by 15
Relling, A. E., Reynolds, C. K., & Loerch, S. C. (2010) · Journal of Animal Science · doi:10.2527/jas.2010-2976 · Cited by 15
Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus
Joffe, D. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090230 · Cited by 15
Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
Pelluri, R., Kongara, S., Nagasubramanian, V. R., Mahadevan, S., & Chimakurthy, J. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02003-9 · Cited by 14
Carbon‐14 labeling of Saxagliptin (BMS‐477118)
Cao, K., Bonacorsi, S. J., Balasubramanian, B. N., Hanson, R. L., Manchand, P. S., Godfrey, J. D., Fox, R., Christopher, L. J., Su, H. L., & Iyer, R. A. (2007) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1450 · Cited by 13
Insulin actions in vivo : glucose metabolism
Ferrannini, E., & DeFronzo, R. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch14 · Cited by 12
Sato, Y., Kamada, T., & Yamauchi, A. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0016 · Cited by 11
Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Yki‐Järvinen, H. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0028-0 · Cited by 11
Liraglutide for type 2 diabetes mellitus
Kela, R., Khunti, K., & Davies, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.583641 · Cited by 13
Augstein, P., Berg, S., Heinke, P., Altmann, S., Salzsieder, E., Demuth, H. U., & Freyse, E. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00813.x · Cited by 10
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2024) · Peptides · doi:10.1016/j.peptides.2024.171256 · Cited by 9
Hupfeld, C. J., & Olefsky, J. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00040-8 · Cited by 9
Inoue, H., Shintani, N., Sakurai, Y., Higashi, S., Hayata‐Takano, A., Baba, A., & Hashimoto, H. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00027 · Cited by 9
Incretin enhancers, incretin mimetics – from therapeutic concept to clinical application
Winkler, G. (2007) · Orvosi Hetilap · doi:10.1556/oh.2007.28093 · Cited by 9
Drug-Induced Endocrine and Metabolic Disorders
Salem, C. B., Slim, R., Elouni, B., Hmouda, H., & Bouraoui, K. (2007) · Drug Safety · doi:10.2165/00002018-200730080-00009 · Cited by 9
Design of Insulin Variants for Improved Treatment of Diabetes
Høeg-Jensen, T. (2009) · Wiley eBooks · doi:10.1002/9780470749708.ch7 · Cited by 8
Future Drug Treatments for Type 2 Diabetes
Bailey, C. J. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch60 · Cited by 7
Åhrén, B. (2009) · Insulin · doi:10.1016/s1557-0843(09)80004-3 · Cited by 7
Incretin physiology and its role in type 2 diabetes mellitus.
Svec, F. (2010) · PubMed · Cited by 6
Incretin Based Therapies in Type 2 Diabetes Mellitus
Göksu, U. A., & Ünal, A. (2017) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2017.94830 · Cited by 6
Awareness of pathophysiological concepts of type 2 diabetes—A survey in 847 physicians
Busse, F. P., Denti, V., & Stümvoll, M. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.09.037 · Cited by 6
Vildagliptin: novel pharmacological approach to treat Type 2 diabetes
Åhrén, B. (2008) · Therapy · doi:10.2217/14750708.5.1.79 · Cited by 6
Green, J. B., & Feinglos, M. N. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0060-0 · Cited by 6
Current developments in the treatment of diabetes: the incretin therapies
Russell-Jones, D. L. (2010) · The British Journal of Diabetes · doi:10.1177/1474651409357266 · Cited by 6
Gastroesophageal reflux disease in diabetic patients: a systematic review
Promberger, R., Gadenstätter, M., Ciovica, R., Schwab, G. P., & Neumayer, C. (2007) · European surgery. Supplement/European surgery · doi:10.1007/s10353-007-0366-9 · Cited by 5
Hupfeld, C. J., Courtney, C. H., & Olefsky, J. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00041-1 · Cited by 7
Zhou, H., Shi, T., Yan, J., Chen, X., Liao, L., Zhao, S., Fang, H., & Zhuang, R. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5128 · Cited by 5
Diabetes Mellitus as Dysfunction of Interactions among all Organs: “Ominous Orchestra of Organs”
Koshiyama, H., Ogawa, Y., Tanaka, K., & Tanaka, I. (2008) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s552 · Cited by 5
cd26 Knockdown Negatively Affects Porcine Parthenogenetic Preimplantation Embryo Development
Hwang, I., Shim, J., Oh, K. B., Lee, H., & Park, M. (2022) · Animals · doi:10.3390/ani12131662 · Cited by 4
Future Drug Treatments for Type 2 Diabetes
Bailey, C. J. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch67 · Cited by 5
Udiawar, M., & Bain, S. C. (2012) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s7283 · Cited by 4
Pharmacological therapy of hyperglycaemia in type 2 diabetes mellitus
Bailey, C. J., & Davies, M. J. (2011) · doi:10.1093/med/9780199235292.003.1373 · Cited by 4
Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs
Jermendy, G. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29207 · Cited by 4
Exercise therapy in Type 2 Diabetes
Praet, S. (2007) · Research Publications (Maastricht University) · doi:10.26481/dis.20071214sp · Cited by 4
Combination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 3
Pharmacotherapy for Weight Loss
Lutz, T. A., & Asarian, L. (2017) · CRC Press eBooks · doi:10.1201/9781315120171-13 · Cited by 3
Glucagon-like Peptide-1 Receptor Agonists: Limitless Potential
Demidova, T. Y., & Kozhevnikov, A. A. (2020) · Doctor Ru · doi:10.31550/1727-2378-2020-19-2-6-12 · Cited by 3
Laferrère, B. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.03.001 · Cited by 3
The new diabetes inhalers: New tools for the clinician
Cefalu, W. T. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0026-2 · Cited by 3
Editorial: Proglucagon-Derived Peptides
Flatt, P. R., Knop, F. K., & Tarasov, A. I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.776871 · Cited by 3
Discordance between fasting plasma glucose and A1c in the diagnosis and management of diabetes
Sarinnapakorn, V., Deerochanawong, C., Niramitmahapanya, S., Napartivaumnuay, N., & Treesaranuwattana, T. (2021) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2021.12.1.0521 · Cited by 2
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients
Teti, C., Talco, M., Albertelli, M., Albanese, V., Minuto, M. N., Aglialoro, A., Monachesi, M., Viviani, G. L., Gatto, F., Ferone, D., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01106-6 · Cited by 2
Brice, K. R., & Tzefos, M. (2011) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s4086 · Cited by 2
Metabolic and Endocrine Physiology in Obesity
Álvarez-Castro, P., Sangiao‐Alvarellos, S., & Cordido, F. (2012) · Wiley eBooks · doi:10.1002/9781119962083.ch4 · Cited by 2
Treatment Considerations for Diabetes: A Pharmacist’s Guide to Improving Care in the Elderly
Nicholas, A., Nadeau, D. A., & Johnson, A. C. L. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190009333160 · Cited by 2
L’internista ospedaliero nella gestione del paziente diabetico complesso
Magnani, G. E. L., Beltramello, G., Brancato, D., Fontanella, A., & Nardi, R. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.q.2018.2 · Cited by 2
Lambe, C., & Goulet, O. (2021) · Springer eBooks · doi:10.1007/978-3-030-80068-0_43 · Cited by 2
The association of DNA methylation patterns in TCF7L2 and GIPR genes with Type 2 Diabetes
Canivell, S. (2014) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · Cited by 3
EFFECT OF GUT PEPTIDES ON HYPOTHALAMIC mRNA CONCENTRATION AND DRY MATTER INTAKE IN RUMINANTS
Relling, A. E. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 2
Metadata
- Authors
- Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, J. J.
- ORCID
- Holst, J. J.
- Venue
- Diabetologia
- Published
- 2006-01-14
- Volume
- 49
- Issue
- 2
- Pages
- 253-260
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2082032596
- Cited by
- 228
- References
- 95
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 5 · 2019: 6 · 2018: 6 · 2017: 5 · 2016: 10 · 2015: 13 · 2014: 7 · 2013: 13 · 2012: 16
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- European Foundation for the Study of Diabetes
- Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, incretins, glucose-dependent insulinotropic polypeptide, proglucagon, type 2 diabetes, insulin secretion, incretin mimetics, DPP-4 inhibitors, dipeptidyl peptidase IV, HbA1c, weight loss, oral antidiabetic drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Insulin Secretion, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Intestines, Peptides, Protease Inhibitors, Venoms, Receptors, Glucagon, Dipeptidyl Peptidase 4, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.